

ABIOMED INC  
Form 8-K  
January 20, 2006

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549



**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934**



Edgar Filing: ABIOMED INC - Form 8-K

Date of Report: **January 13, 2006**

(Date of earliest event reported)

## **ABIOMED, Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or Other Jurisdiction of  
Incorporation)

**04-2743260**  
(IRS Employer Identification  
Number)

**001-09585**  
(Commission File Number)

**22 Cherry Hill Drive**

Edgar Filing: ABIOMED INC - Form 8-K

**Danvers, MA 01923**

(Address of Principal Executive Offices, including Zip Code)

**(978) 777-5410**

(Registrant's Telephone Number, including Area Code)

**Not Applicable**

## Edgar Filing: ABIOMED INC - Form 8-K

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 1.01            Entry into a Material Definitive Agreement.**

On January 13, 2006, our Board of Directors awarded our new director Ronald W. Dollens a non-qualified stock option to purchase 25,000 shares of our common stock. These options were issued under our 2000 Stock Incentive Plan and will expire ten years from the date of grant if not exercised. The option has an exercise price of \$10.27 per share and vests in annual increments of 20% beginning on January 13, 2007.



**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

ABIOMED, Inc.

By: */s/ Daniel J. Sutherby*  
Daniel J. Sutherby  
**Principal Financial Officer**





Date: January 20, 2006